Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27612215 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL5439442 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2865352 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6611266 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| Lithium Ion SCHEMBL6611264 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2527608 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL4534552 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2792760 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL5435616 | 0.81 | GPR119 (0.53) | NPC1RAB9AMEN1KMT2AHTT | |
| SCHEMBL450914 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100398535-C | Piperidine derivatives and their use as modulators of chemokine receptor (especially CCR5) activity | ASTRAZENECA AB (SE) | 2008-07-02 | — | — | CN | disclosed |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-7192973-B2 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5) | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| CN-1585763-A | Piperidine derivatives and their use as modulators of chemokine receptor activity especially CCR5 | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | CN | disclosed |
| US-20040267016-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1448548-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042205-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267016-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | CCR5, CCR2, CCR1 | SMN1; SMN2 4013/4885NPC1 446/4885RAB9A 1866/4885 |
| US-20070161646-A1 | Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5) | CCR5, CCR2, CCL5 | SMN1; SMN2 4133/4885NPC1 518/4885RAB9A 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.